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Quantitative MRI radiomics in the prediction of molecular
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data set
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Margarita Zuley7, Jose M Net8, Elizabeth Sutton9, Gary J Whitman10, Elizabeth Morris9, Charles M Perou5, Yuan Ji2,11 and
Maryellen L Giger1
Using quantitative radiomics, we demonstrate that computer-extracted magnetic resonance (MR) image-based tumor phenotypes
can be predictive of the molecular classification of invasive breast cancers. Radiomics analysis was performed on 91 MRIs of biopsy-
proven invasive breast cancers from National Cancer Institute’s multi-institutional TCGA/TCIA. Immunohistochemistry molecular
classification was performed including estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and
for 84 cases, the molecular subtype (normal-like, luminal A, luminal B, HER2-enriched, and basal-like). Computerized quantitative
image analysis included: three-dimensional lesion segmentation, phenotype extraction, and leave-one-case-out cross validation
involving stepwise feature selection and linear discriminant analysis. The performance of the classifier model for molecular
subtyping was evaluated using receiver operating characteristic analysis. The computer-extracted tumor phenotypes were able to
distinguish between molecular prognostic indicators; area under the ROC curve values of 0.89, 0.69, 0.65, and 0.67 in the tasks of
distinguishing between ER+ versus ER− , PR+ versus PR− , HER2+ versus HER2− , and triple-negative versus others, respectively.
Statistically significant associations between tumor phenotypes and receptor status were observed. More aggressive cancers are
likely to be larger in size with more heterogeneity in their contrast enhancement. Even after controlling for tumor size, a statistically
significant trend was observed within each size group (P= 0.04 for lesions ⩽ 2 cm; P= 0.02 for lesions 42 to ⩽ 5 cm) as with the
entire data set (P-value = 0.006) for the relationship between enhancement texture (entropy) and molecular subtypes (normal-like,
luminal A, luminal B, HER2-enriched, basal-like). In conclusion, computer-extracted image phenotypes show promise for high-
throughput discrimination of breast cancer subtypes and may yield a quantitative predictive signature for advancing precision
medicine.
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INTRODUCTION
Breast cancer is the most commonly diagnosed cancer among
women in North America, and it is the second leading cause of
cancer death in women.1 On the basis of receptor status, breast
cancer can be classified into different subtypes. The three clinically
most-useful receptors in breast cancer cells, because they dictate
therapy, are the estrogen receptor (ER), progesterone receptor
(PR), and human epidermal growth factor receptor 2 (HER2). HER2-
positive breast cancers tend to be more aggressive and have a
poorer prognosis than HER2-negative cancers, and ER-positive and
PR-positive cases have lower risks of mortality compared with
women with ER-negative and/or PR-negative disease.2–5 Triple-
negative (TN) cases (negative for all three receptors) relapse more
quickly, and thus account for a large portion of breast cancer
deaths after diagnosis.2–4,6,7 By considering gene expression
measurements, breast cancer can be categorized into several
molecular subtypes, such as normal-like, luminal A, luminal B,
HER2-enriched, and basal-like. Different molecular and receptor
characterized subtypes have different prognoses and respond
differently to specific therapies.8–12
An important project facilitating research in the molecular and
genetic landscape of breast cancer is The Cancer Genome Atlas
(TCGA), sponsored by the National Cancer Institute (NCI) and
National Human Genome Research Institute.13,14 The Cancer
Imaging Archive (TCIA) project is the imaging counterpart of the
TCGA and has the goal to promote cross-disciplinary research to
better understand the relationship between imaging phenotypes
(i.e., radiomics) and genomic markers (i.e., genomics).13,14 Various
investigators have been developing computerized image analysis
for computer-aided diagnosis and the quantitative characteriza-
tion (i.e., radiomics) of breast cancers on clinical images.15,16 It is
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important to understand the difference between ‘radiomics’ and
‘radiogenomics’.17 ‘Radiomics’ refers to the high-throughput
extraction of quantitative features from images, i.e., conversion
of images to mineable data, and subsequently using these data for
decision support, including patient outcome. ‘Radiogenomics’ or
‘imaging genomics’ refers to the study of the associations
between radiomic data (imaging features) and genomic patterns.
It should be noted that radiogenomics is also used in the field of
radiation oncology to refer to the study of genetic variation
associated with effects from radiation therapy. Radiomics in breast
cancer research is being conducted for the diagnostic differentia-
tion of malignant from benign tumors as well as for prognosis in
terms of invasiveness—identifying ductal carcinoma in situ and
invasive ductal carcinoma, pathologic stage, lymph node involve-
ment, molecular subtypes, and genomics.18–30 Bhooshan et al.19,20
related dynamic contrast-enhanced magnetic resonance imaging
(DCE-MRI) radiomic features to breast cancer invasiveness and
cancer type. Agner et al.22 extracted image-based features and
used them to differentiate the TN cancers from other molecular
subtypes. Mazurowski et al.24 analyzed 48 TCIA breast MRI cases,
and related MRI enhancement dynamics to the luminal B subtype.
Grimm et al.25 discovered relationships between MRI imaging
features and luminal A and luminal B cancer molecular subtypes.
Yamamoto et al.26,27 showed the association between radio-
genomic biomarkers with early metastasis. Ashraf et al.28 found
that intrinsic imaging phenotypes correlated with risk of
recurrence score defined by Oncotype DX. Yamaguchi et al.29
studied the relationship between heterogeneous kinetic curve
pattern and molecular subtype. Blaschke et al.30 reported that
HER2-positive tumors have a greater portion of their tumor with
rapid uptake compared with other molecular subtypes. In this
paper, we demonstrate, for biopsy-proven invasive breast cancers,
the relationships between molecular classifications of breast
tumors, in terms of ER, PR, HER2, TN, and intrinsic molecular
subtypes as determined from PAM50 microarray assay, and MRI
phenotypes. We aim to provide a quantitative MRI-based
signature to clinicians for assessing the prognosis of breast cancer
and potentially the patient treatment strategy in personalized
medicine.
RESULTS
From receiver operating characteristic (ROC) analysis, the
performance of the MRI phenotypic signatures in the task of
distinguishing between clinical receptor status yielded area under
the ROC curve (AUC) values of 0.89 (P-value o0.0001), 0.69
(P-value=0.0112), 0.65 (P-value=0.0491), and 0.67 (P-value=0.0404)
in the tasks of distinguishing between ER+ versus ER− , PR+ versus
PR− , HER2+ versus HER2− , and TN versus all others, respectively.
Example cases, one ER-positive tumor and one ER-negative tumor,
with tumor segmentation outlines from our computerized lesion
segmentation method, are shown in Figure 1, along with
computer-extracted image phenotype (CEIP) values (and ranges)
for size, irregularity, and contrast enhancement heterogeneity.
The box plots of MRI phenotypes of size, shape, and
enhancement texture based on the receptor status (ER, PR,
HER2, TN) are shown in Figures 2–4. As shown in Table 1, which
gives the average values and standard deviations, the ER-negative
cases tended to have larger lesion size, were more irregular in
shape, and were more heterogeneous in contrast enhancement
Figure 1. Example cases including segmentation outlines obtained from the computer segmentation method. (a) ER-positive example;
(b) ER-negative example; (c) CEIP values (and ranges) for size, irregularity, and enhancement texture for two example cases. CEIP, computer-
extracted image phenotypes; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; MRI, magnetic resonance imaging.
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Figure 2. Relationship between MRI phenotype of size (effective
diameter) and receptor status (a: ER; b: PR; c: HER2; d: TN). The
P-values from the Mann–Whitney U-test are 0.001, 0.14, 1.0, and
0.006 for ER, PR, HER2, and TN, respectively. ER, estrogen receptor;
HER2, human epidermal growth factor receptor 2; MRI, magnetic
resonance imaging; PR, progesterone receptor; TN, triple negative.
Figure 3. Relationship between MRI phenotype of lesion shape
(irregularity) and receptor status (a: ER; b: PR; c: HER2; d: TN).The
P-values from the Mann–Whitney U-test are 0.23, 0.43, 0.36, and 0.03
for ER, PR, HER2, and TN, respectively. ER, estrogen receptor; HER2,
human epidermal growth factor receptor 2; MRI, magnetic
resonance imaging; PR, progesterone receptor; TN, triple negative.
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texture than those of the ER+ cases. The PR− cases tended also,
on average, to be larger in size, more irregular in shape, and
more heterogeneous in contrast enhancement than those of the
PR+ cases. The TN cases also showed similar trends as compared
with non-TN cases. Mann–Whitney test results showed the
differences in the mean values of some MRI phenotypes of size
and enhancement texture across the molecular classifications
(Table 1; Figures 2–4).
From the Kendall test, examination of the relationship between
the MRI phenotype of size (effective diameter) and cancer subtype
demonstrated a statistically significant positive trend for size with
molecular subtypes (P-value = 0.01; Figure 5). Similarly, a positive
trend was also observed between the MRI phenotype of
enhancement texture (entropy) and cancer subtype, with the
Kendall test indicating statistical significance (P-value = 0.006;
Figure 6). Results indicate that the more aggressive cancers are
likely to be larger in size with more heterogeneity in their contrast
enhancement. Even after controlling for tumor size, a similar
statistically significant trend was observed within each size group
(P= 0.04 for lesions size ⩽ 2 cm; P= 0.02 for lesions size 42 to
⩽ 5 cm) as with the entire data set for the relationship between
MRI phenotype of enhancement texture (entropy) and the cancer
subtype (Figure 7).
DISCUSSION
The results from this study indicate that quantitative MRI analysis
shows promise as a means for high-throughput image-based
phenotyping in the discrimination of breast cancer subtypes.
Note that in this pilot study, we were interested in only the
performance of the MRI phenotypes, thus we assessed the
performance of the image-based phenotypes without investigat-
ing the impact on radiologist assessment, with or without the
combination of genetic information derived from pathology.
Our results indicate that ER-negative cases may be larger, more
irregular in shape, more heterogeneous, and have a faster contrast
uptake rate than those of ER-positive cases (Table 1). Similar
observations were also reported by Chen et al.31 in a correlation
study between ER status and breast MRI radiomics. These
phenotypes reiterate prior literature, capturing on imaging that
ER− tumors have higher microvessel density,32 higher levels of
vascular endothelial growth factor,33 and higher proliferative
activity.33 PR-negative cases also tended to be larger, more
irregular in shape, more heterogeneous, and have a faster contrast
uptake than those of PR-positive cases—though not statistically
significant (Table 1). These observations may visually convey the
existing evidence that PR− cancers tend to have high growth
factor signaling.34 In other words, PR loss (and correlative imaging
phenotypes) may serve as a surrogate marker for excessive growth
factor receptor activation.
TN cases, on average, tended to be larger, more irregular in
shape, more heterogeneous, and have a faster contrast uptake
rate as compared with all the other cases (Table 1). Similar
observations were reported by Agner et al.22 who showed more
lesion heterogeneity in TN breast cancers relative to non-TN
cancers. Youk et al.23 reported that larger tumor size was
significantly associated with TN breast cancer. Finally, basal-like
cancers appeared more heterogeneous in enhancement texture
patterns (Figures 6 and 7). The majority of basal-like cancer cases
(9 out of 10) in this study were TN cases (Table 2). Basal-like breast
cancer is defined not only by the absence of ER, PR and HER2
receptors, but also by the over expression of oncogenes that favor
cell proliferation,35 suggesting why basal-like tumors tend to be
larger in size. We posit that imaging phenotypes like hetero-
geneity and contrast enhancement, evident on dynamic contrast-
enhanced breast MRI, capture and convey pathophysiologic
characteristics like proliferation and angiogenesis and have the
further potential to provide clues to more accurate prognosis and
optimal treatment.
It is interesting to note that enhancement texture (especially
heterogeneity) emerged as an important discriminatory indicator.
Figure 4. Relationship between MRI phenotype of enhancement
texture (entropy) and receptor status (a: ER; b: PR; c: HER2; d: TN).
The P-values from the Mann–Whitney U-test are 0.08, 0.03, 0.93, and
0.13 for ER, PR, HER2, and TN, respectively. ER, estrogen receptor;
HER2, human epidermal growth factor receptor 2; MRI, magnetic
resonance imaging; PR, progesterone receptor; TN, triple negative.
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Table 1. Results from the Mann–Whitney U-test indicating association between MRI phenotypes and molecular classifications for phenotypes shown
in Figures 2–4
Classification task Number of tumors MRI phenotype Mean value (s.d.) positive versus negative P-value Significance level (αT = 0.05)
ER+ versus ER− 91 (77 vs. 14) Effective diameter 17.6 mm (5.6) vs. 24.8 mm (10.4) 0.001a 0.0167
Irregularity 0.61 (0.11) vs. 0.65 (0.11) 0.23 0.05
Entropy 6.40 (0.11) vs. 6.45 (0.09) 0.08 0.025
PR+ versus PR− 91 (72 vs.19) Effective diameter 18.0 mm (5.6) vs. 21.6 mm (10.5) 0.14 0.025
Irregularity 0.61 (0.11) vs. 0.63 (0.10) 0.43 0.05
Entropy 6.39 (0.11) vs. 6.45 (0.07) 0.03 0.0167
HER2+ versus HER2− 91 (19 vs. 72) Effective diameter 18.4 mm (5.7) vs. 18.8 mm (7.3) 1.0 0.05
Irregularity 0.59 (0.12) vs. 0.62 (0.11) 0.36 0.0167
Entropy 6.41 (0.10) vs. 6.40 (0.11) 0.93 0.025
TN versus others 91 (11 vs. 80) Effective diameter 17.8 mm (5.6) vs. 25.6 (11.5) 0.006a 0.0167
Irregularity 0.60 (0.11) vs. 0.68 (0.09) 0.03 0.025
Entropy 6.40 (0.10) vs. 6.45 (0.10) 0.13 0.05
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; MRI, magnetic resonance imaging; PR, progesterone receptor;
TN, triple negative.
aIndicates statistical significance was achieved after correction for multiple comparisons.
Figure 5. Relationship between the MRI phenotype of size (effective diameter) and the molecular subtypes. Shown is a statistically significant
trend between size and molecular subtype (P-value of 0.01 from the Kendall test). HER2, human epidermal growth factor receptor 2;
MRI, magnetic resonance imaging.
Figure 6. Relationship between the MRI phenotypes of enhancement texture (entropy) and the molecular subtypes. The enhancement texture
is calculated at the first-post-contrast MR image thus quantitatively characterizing the heterogeneous uptake of contrast within the tumor.
Shown is a statistically significant trend between entropy and molecular subtype (P-value of 0.006 from the Kendall test). HER2, human
epidermal growth factor receptor 2; MRI, magnetic resonance imaging.
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As the enhancement texture is calculated at the first post-contrast
time point of the MR image, this enhancement texture phenotype
quantitatively characterizes the heterogeneous nature of the
contrast uptake within a breast tumor.36 The larger the enhance-
ment texture entropy, the more heterogeneous the tumor. It is
important to note that, based on our analysis stratified by tumor
size, we believe that molecular subtype is related to the hete-
rogeneous nature of contrast uptake within the breast tumor and
not just dependent on lesion size. Waugh et al.37 also performed
texture analysis in classification of primary breast cancer, and the
similar observation was reported that HER2-enriched and TN
cancers showed a significant increase in entropy value relative to
Figure 7. Relationship between the MRI phenotypes of enhancement texture (entropy) and the molecular subtypes based on size strata
(a: lesion size⩽ 2 cm; b: lesion size 42 cm to ⩽ 5 cm). Shown are the statistically significant trends between entropy and molecular subtype
(P-values of 0.04 and 0.02, respectively, from the Kendall tests). HER2, human epidermal growth factor receptor 2; MRI, magnetic resonance
imaging.




ER+ ER− PR+ PR− HER2+ HER2− Triple negative Others
All cases 91 85% (77/91) 15% (14/91) 79% (72/91) 21% (19/91) 21% (19/91) 79% (72/91) 12% (11/91) 88% (80/91)
Normal-like 5% (4/84) 100% (4/4) 0% (0/4) 100% (4/4) 0% (0/4) 25% (1/4) 75% (3/4) 0% (0/4) 100% (4/4)
Luminal A 65% (55/84) 100% (55/55) 0% (0/55) 95% (52/55) 5% (3/55) 15% (8/55) 85% (47/55) 0% (0/55) 100% (55/55)
Luminal B 12% (10/84) 100% (10/10) 0% (0/10) 80% (8/10) 20% (2/10) 40% (4/10) 60% (6/10) 0% (0/10) 100% (10/10)
HER2-enriched 6% (5/84) 60% (3/5) 40% (2/5) 40% (2/5) 60% (3/5) 100% (5/5) 0% (0/5) 0% (0/5) 100% (5/5)
Basal-like 12% (10/84) 10% (1/10) 90% (9/10) 10% (1/10) 90% (9/10) 10% (1/10) 90% (9/10) 90% (9/10) 10% (1/10)
Not determined 7 57% (4/7) 43% (3/7) 71% (5/7) 29% (2/7) 0% (0/7) 100% (7/7) 29% (2/7) 71% (5/7)
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.
Quantitative MRI radiomics
H Li et al
6
npj Breast Cancer (2016) 16012 © 2016 Breast Cancer Research Foundation/Macmillan Publishers Limited
luminal A and luminal B cancers. A study by Grimm et al.25 showed
that imaging features can predict luminal A and luminal
B molecular subtypes, but not HER2-enriched and basal-like types.
The evidence from our and others’ work indicate that further
study is warranted in order to better understand the relationships
between enhancement texture and molecular subtypes.
There are several studies19,20,24,29,30 in the literature that have
related breast MRI kinetics to cancer subtype. Bhooshan et al.19,20
studied 353 MRI cases and correlated breast MRI radiomics
features to non-invasive and invasive cancer types. Mazurowski
et al.24 performed radiogenomic analysis on a subset of 48 cases
from TCIA to determine whether enhancement dynamics could
predict the luminal B subtype. A study by Yamaguchi et al.29
investigated the connection between kinetic curve pattern and
molecular subtypes. Blaschke et al.30 reported that HER2-enriched
tumors have a larger volume of rapid early uptake compared with
other molecular types. In our study, the faster contrast uptake was
observed in ER− , PR− , and TN cancers relative to ER+, PR+ and
non-TN cancers. All these studies indicate that enhancement
kinetics may reflect underlying tumor biological characteristics
(in vivo) and warrant further research to understand these
phenomena more fully.
These are several limitations in our study. The MR images used
in this study were acquired more than 10 years ago by four
different institutions, which may have had different acquisition
protocols, different weight-based dosing regimen for contrast
agents, and different time resolution of post-contrast sequences,
and thus, these images may not reflect current MRI technology,
which has advanced substantially during the past decade. Given
higher signal-to-noise, improved spatial resolution, and more
standardized imaging acquisition protocols, we would expect to
see even more associations with molecular subtype. The large
majority of cases came from only two sites. This has potential to
introduce site bias. Thus, we performed leave-one-case-out cross
validation to minimize the bias, and not to overestimate the
performance on this limited data set. In addition, our patient
population was predetermined by TCGA inclusion criteria. Cases
included in the TCGA data set, in general, required surgical
resection of at least 200–300 mg of tissue for deep genomic and
proteomic analyses and all were acquired prior to any treatment.
Breast MRIs were included only if they were performed prior to
surgical resection. Thus, our results can only be generalized to this
population. Another limitation of our study was that the patient
sample was relatively small since currently breast MR images are
not available for most of the TCGA breast cancer cases. Database
bias was limited, however, by performing a cross validation for
each molecular classification assessment (such as distinguishing
between ER+ and ER− cases). Also, for some of the classification
tasks the subtype prevalence was rather skewed (e.g., 11 TN
versus 80 non-TN cancers) and hence results of this pilot study are
somewhat preliminary. Despite all these limitations, the TCGA data
set is still the largest publicly available data set for radiogenomic
breast cancer research.
Future work will include studies on a larger clinical data set to
verify the results from this preliminary study and further assess the
role of the MRI phenotypes in combination with human visual
clinical assessment and/or genomic information. It is our hope
that, ultimately, merging imaging phenotypes with genomic data
may lead to improved predictors.
We have demonstrated that there are statistically significant
associations between image-based tumor phenotypes and
receptor status. In addition, a statistically significant trend was
observed between enhancement texture and intrinsic molecular
subtypes of normal-like, luminal A, luminal B, HER2-enriched, and
basal-like. The results from this study have the potential to provide
insight into the underlying tumor biology including tumor
heterogeneity. Also, using imaging phenotypes to identify
molecular subtypes may aid in clinical diagnosis and treatment
planning. Such imaging data and associated radiomics may
serve as a “virtual biopsy”, which is non-invasive, includes the
entire tumor, and is repeatable. In summary, computer-extracted
MRI phenotypes show promise as a means for high-throughput
discrimination of breast cancer subtypes and may yield a




Data analyzed in this study had been collected by the NCI under
Institutional Review Board-approved HIPAA compliant protocols. We had
access to de-identified data only, including the MR image data and the
molecular classifications from the TCGA breast invasive carcinoma initiative
for which breast cancer cases were solicited from cancer centers across the
United States. The clinical, pathology, and molecular classification data
were downloaded from the TCGA data portal using the software
‘TCGA-Assembler’.38 In addition, the classification of cancer subtypes was
obtained from RNA sequencing gene expression data determined in the
Perou lab at University of North Carolina, yielding normal-like, luminal A,
luminal B, HER2-enriched, and basal-like subtype calls.39,40
In the TCIA, a MRI data set of 108 examinations was available at the time
of this study (http://www.cancerimagingarchive.net). To reduce potential
image acquisition variation, we analyzed only breast MRI studies that were
similar in acquisition and technique, namely, MRIs that were acquired on a
1.5 Tesla magnet strength using GE (GE Medical Systems, Milwaukee, WI,
USA) scanners and protocols; a total of 93 cases. One case with missing
images in the dynamic sequence and one case without genotyping data
were excluded from the study. Thus, a study database of 91 breast cancer
patients resulted (Table 2) with images contributed by four institutions:
Memorial Sloan Kettering Cancer Center, Mayo Clinic, University of
Pittsburgh Medical Center, and Roswell Park Cancer Institute. The
cases contributed by each institution were 9 (date range 1999–2002),
5 (1999–2003), 46 (1999–2004), and 31 (1999–2002), respectively. The
average age of the 91 patients was 53.6 years with a standard deviation of
11.5 years and a range from 29 to 82 years with a median of 53 years. All
patients had confirmed breast cancer. Out of the 91 invasive breast
carcinoma cases, 79 were ductal carcinoma, 10 were lobular carcinoma,
and 2 were mixed. The MRI examinations had been performed for cancer
staging purpose prior to any treatment. In this paper, we will refer to breast
cancer cells with or without the investigated hormone receptors as ER+,
ER− , PR+, PR− , HER2+, and HER2− , respectively. For 84 of the 91 cases in
the study, gene expression classifications of ‘intrinsic’ cancer molecular
subtypes normal-like, luminal A, luminal B, HER2-enriched, and basal-like
were also available. Note that this TCGA/TCIA data set of breast cancer
cases is significant (although limited in size) since it represented the largest
publicly available set of breast MRIs that had corresponding clinical data,
pathologic data, and genomic data.
Image data
MRIs had been acquired with a standard double breast coil on a 1.5T GE
whole-body MRI system (GE Medical Systems). Only T1-weighted dynamic
contrast-enhanced MR images were used in this study. The imaging
protocols included one pre- and three to five post-contrast images
obtained using a T1-weighted three-dimensional spoiled gradient echo
sequence with a gadolinium-based contrast agent. In-plane resolution
ranged from 0.53 to 0.86 mm, and spacing between slices ranged from 2 to
3 mm.
Radiologist review of MR images
Each breast MRI examination was reviewed, using ClearCanvas41,42 (http://
www.radiology.northwestern.edu/research/areas-of-research/Imaging-Infor
matics-home/Software%20Tools.html) (ClearCanvas, Toronto, ON, Canada),
by 3 of 11 expert board-certified breast radiologists who were blinded to
outcomes and who each annotated the cases independently to yield
information on the approximate center location of each breast cancer. The
breast imaging experience of the 11 readers was 17 years on average with
a standard deviation of 6 years and a range from 4 to 25 years with a
median of 15 years. For the reported study, the only input to the computer
was the radiologist-determined tumor center location (by consensus) on
MRI.
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Extraction of MRI-based tumor phenotypes
Given the approximate tumor center location on the MRI, each primary
breast tumor was automatically segmented in three-dimensional from the
surrounding parenchyma using a fuzzy c-means clustering-based method,
described in detail elsewhere.43
A total of 38 mathematical descriptors of the breast tumors were
extracted from the computer-derived tumor segmentations (Supple-
mentary Appendix Table A1). These CEIPs can be divided into six MRI
phenotypic categories describing (a) size, (b) shape, (c) morphology,
(d) enhancement texture, (e) kinetic curve assessment, and (f) enhance-
ment-variance kinetic features.36,44–49
The tumor size CEIPs yield information on the tumor effective diameter,
volume, maximum linear size, and surface area. Effective diameter is the
diameter of a sphere with the same volume as the tumor. Maximum linear
size is the maximum distance between any two voxels in the three-
dimensional tumor. Both effective diameter and maximum linear size were
calculated from computer-segmented three-dimensional breast tumors.
Note that the standard clinically-measured tumor size, as measured by the
radiologists, is the largest length on MRI, and it was determined by
radiologists using ClearCanvas software on a two-dimensional MR slice. For
multi-focal lesions, only the primary/largest lesion was measured for tumor
size. The correlation coefficients between clinical-measured tumor size and
four computer size phenotypes ranged from 0.63 (surface area) to 0.79
(effective diameter). The computer-extracted size phenotype, measuring
effective diameter, correlated the most with the radiologist’s size measure,
and thus, was used to group the tumors into different size groups based
on TNM staging criteria.50 Tumor CEIPs of shape include sphericity and
irregularity.
Morphological CEIPs combined tumor shape and margin characteristics,
and include CEIPs of margin sharpness, variance of margin sharpness, and
variance of radial gradient histogram, which are used to assess tumor
spiculation.44
Enhancement texture tumor CEIPs characterize the tumor textural
properties of the contrast-enhanced tumors on the first post-contrast
images, i.e., the heterogeneity of the uptake, and thus potentially the
heterogeneity of angiogenesis within the tumor. These texture CEIPs were
calculated from the gray-level co-occurrence matrix, with extracted
features including image homogeneity, image linearity, gray-level depen-
dence, local image variation, and randomness.36,45
Kinetic curve assessment tumor CEIPs characterize the physiological
process of the uptake and washout nature of the contrast agent in a breast
tumor during the dynamic imaging series and were calculated from the
kinetic curve obtained from the most enhancing voxels within the tumor.
The kinetic features include maximum contrast enhancement, time to
peak, uptake rate, washout rate, curve shape index, and signal enhance-
ment ratio.19,46,48,49 Enhancement–variance kinetics tumor CEIPs
characterize the time course of the spatial variance of the enhancement
within a breast tumor, and those extracted features include maximum
variance of enhancement, time to peak, variance increase rate, and
variance decrease rate.47
Determination of the clinical receptor status
ER status and PR status of our data set samples were obtained from the
TCGA data portal using the open-source software ‘TCGA-Assembler’.38
HER2 status of the samples was obtained from TCGA benchmark paper for
BRCA published in Nature,13 which generated a HER2 call for a sample
based on its molecular data if its clinical HER2 call was missing. The
summary regarding the receptor statuses for the patients used in this
study is listed in Table 2.
Determination of the breast cancer molecular subtypes
The determination of breast cancer intrinsic subtypes was obtained from
the Perou lab at the University of North Carolina, yielding normal-like,
luminal A, luminal B, HER2-enriched, and basal-like cells.39,40 Cancer
subtypes were determined using the PAM50 classifier.40 The training set
used in the PAM50 algorithm is comprised of 50% ER+ samples. However,
in the TCGA data set, there were ~ 80% ER+ samples. In order to normalize
TCGA data similarly to the prevalence of ER in the PAM50 training set,
TCGA RNA sequencing data was sub-sampled for a group of cases with
50% ER+ that included 157 ER− and 157 randomly selected ER+ cases with
a freeze date of 7 September 2012. The median gene expression value for
the subset was determined and applied to the full TCGA data set prior to
running the PAM50 algorithm to determine the cancer subtypes.40
Statistical analysis of the prediction of molecular classifications
and cancer subtypes
We assessed the performances of the MRI CEIPs in four classification tasks
based on the immunohistochemistry molecular classifications: (i) estrogen
(ER+ versus ER− ), (ii) progesterone (PR+ versus PR− ), (iii) HER2 (HER2+
versus HER2− ), and (iv) TN (TN versus others) receptor status. Receiver
operating characteristic (ROC) analysis was used to assess the performance
of each of the four classification tasks. The ROC analysis employed the
semi-parametric ‘proper’ binormal ROC model51–53 using either the CEIPS
or the linear classifier output scores as the decision variable, with the AUC
as the figure of merit. Statistical significance was assessed with respect to
the baseline of random guessing (AUC=0.5). In addition, Mann–Whitney
U-tests were conducted to further investigate the differences in the CEIPs
between the molecular classifications.54
To obtain an approximately unbiased estimate of the classification
accuracy of the predictive models, we conducted a single leave-one-case-
out cross validation including both forward and backward feature selection
and tumor classification. That is, within each iteration of the leave-one-
case-out cross validation, tumor CEIPs were selected and subsequently
used as input to a linear discriminant analysis classifier to yield a classifier
output score for the test case (tumor). The phenotypic combinations
selected in each iteration of the cross validation were tabulated, and after
all iterations, the most frequently selected combination (i.e., phenotypic
signature) was reported for each molecular classification task.
A non-parametric Kendall test55 was conducted between the CEIPs and
the molecular (gene expression) cancer subtypes: normal-like, luminal A,
luminal B, HER2-enriched, and basal-like. The molecular subtypes were
ordered as indicated based on the survival data reported by other
studies56–58 and thus were treated as ordinal variables in the association
study. Normal-like breast tumors are usually small and tend to have very
favorable prognosis.57 Luminal A breast cancers are associated with
favorable prognosis, with fairly high survival rates and low recurrence rates;
the 5-year survival rate is more than 80%.56,58 Women with luminal
B tumors are often diagnosed at a younger age than those with luminal
A cancers and have poorer prognosis than luminal A tumors with five-year
survival rates of approximately 40%.56,58 HER2-enriched breast tumors are
generally intermediate- to high-grade tumors with a 5-year survival rate of
31%.56 Basal-like tumors tend to occur more often in younger women and
African-American women, and are often aggressive and have the worst
prognosis among the breast cancer subtypes.56,58 The Kendall coefficient
tau-b was computed to indicate the association between CEIPs and
molecular subtypes. Moreover, since size is an important prognostic factor,
we also investigated the relationship between image-based phenotypes
and molecular subtypes within each lesion size strata based on TNM
staging criteria, in which the data set was divided into three size groups
based on effective diameters: ⩽ 2 cm (T1); 42 to ⩽ 5 cm (T2); or 45 cm
(T3). There were 51 cases with an effective diameter less or equal to 2 cm,
32 with tumor size between 2 and 5 cm, and only 1 case with a tumor
larger than 5 cm.
The statistical significance threshold was set at a P-value of 0.05 to
indicate statistical significance for a single comparison. However, for
multiple comparisons, the Holm’s t-test59 for multiple comparisons of
significance was employed with evaluate the statistical significance using
an overall significant level αT = 0.05. All in-house analysis routines were
written in MatLab (v.8.0, MathWorks, Natick, MA, USA).
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